DANBIO registry plenary Abs 1112 finds 1 yr retention following a mandatory nationwide infliximab biosimilar-to-biosimilar switch was high. Retention higher in originator-experienced and in pts w/ low disease activity. #ACR22 @RheumNow https://t.co/ZAV2dcVzXl https://t.co/Kti2bZ1pkZ
Links:
Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patie…
http://ow.ly/gmha50Lz2oZ
13-11-2022